Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Safety and Tolerability of Repeat Courses of IM Alefacept

ClinicalTrials.gov ID: NCT00233662

Public ClinicalTrials.gov record NCT00233662. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 2:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Repeat Courses of Intramuscular Administration of Alefacept (LFA-3/IgG1 Fusion Protein) in Patients With Chronic Plaque Psoriasis

Study identification

NCT ID
NCT00233662
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Biogen
Industry
Enrollment
400 participants

Conditions and interventions

Interventions

  • Alefacept Drug

Drug

Eligibility (public fields only)

Age range
16 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2002
Primary completion
Not listed
Completion
Nov 30, 2005
Last update posted
Aug 22, 2023

2002 – 2005

United States locations

U.S. sites
19
U.S. states
14
U.S. cities
18
Facility City State ZIP Site status
University of California, Irvine Irvine California 92697
University of California, San Francisco San Francisco California 94118
Clinical Research Specialists, Inc. Santa Monica California 90404
University of Connecticut Health Center Farmington Connecticut 06430-6231
Loyola University Medical Center Maywood Illinois 60153
Massachusetts General Hospital Boston Massachusetts 02114
Central Dermatology St Louis Missouri 63117
University of Medicine and Dentistry Robert Wood Jonhson Medical School New Brunswick New Jersey 08903-0019
New York University School of Medicine New York New York 10016
The Mount Sinai School of Medicine New York New York 10029-6547
Duke University Medical Center Durham North Carolina 27710
Wake Forest University School of Medicine Winston-Salem North Carolina 27157
University Hospitals of Cleveland Cleveland Ohio 44106-5028
Rivergate Dermatology Goodlettsville Tennessee 37072-2301
Baylor Dermatology Research Center Dallas Texas 75246
MD Anderson Cancer Center Houston Texas 77030
University of Utah School of Medicine Salt Lake City Utah 84132
Virginia Clinical Research, Inc. Norfolk Virginia 23507
Dermatology Associates Seattle Washington 98101

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00233662, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 22, 2023 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00233662 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →